However, a recent report by Guan et al. (147) cautioned that the administration of ACE inhibitors significantly induced adverse clinical outcomes in COVID-19 patients due to severe hypertension, coronary artery disease, and chronic renal failure; hence, further use of ACE inhibitors to treat COVID-19 infections was halted (147–149). The gene discussed is ACE; the disease is COVID-19.